Takeda makes two promotions

Ken Araki and Kouji Iwasaki take up their new roles on 1 January

Japanese pharmaceutical firm Takeda has made two promotions and has established a new Strategic Medical Research Planning division at its Japan Development Centre within the Pharmaceutical Development Division.

Ken Araki, previously senior director in the Corporate Strategy & Planning Department, will become vice president of Global Licensing & Business Development on 1 January 2012.

Meanwhile, Kouji Iwasaki, previously director of Post Market Surveillance, Pharmacovigilance Department within the Pharmaceutical Development Division, will become director of the Strategic Medical Planning division on the same day.

You may also like

Finance

Takeda Pharmaceutical to acquire GammaDelta Therapeutics

Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Finance

Takeda to evaluate Aptamer Group reagents for drug development

Based on oligonucleotide molecules, Optimers (which the company describes as optimised aptamer reagents) can bind specifically to a target molecule to act as an antibody alternative
Finance

Adaptate Biotherapeutics raises $18 m in Series A2 funding

The financing will also support the company’s expansion, including further recruitment and increased laboratory and office space
Finance

Novadiscovery enters clinical simulation collaboration with Takeda

This agreement builds on an existing relationship between the companies that began in 2017
Research & Development

Evox Therapeutics and Takeda sign multitarget rare disease collaboration

Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox’s proprietary exosome technology
Finance

Charles River secures milestone deals with Takeda and HemaCare

The laboratory giant inks deal with global Japanese drugmaker and completes acquisition of the cell and gene products manufacturer
Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Subscribe now